Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Fulcrum Therapeutics (FULC – Research Report) yesterday and set a price target of $37.00. The company’s shares closed last Wednesday at $22.38.
According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of -2.1% and a 37.3% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fulcrum Therapeutics with a $38.33 average price target, which is a 78.3% upside from current levels. In a report issued on March 22, H.C. Wainwright also maintained a Buy rating on the stock with a $40.00 price target.
Fulcrum Therapeutics’ market cap is currently $874.1M and has a P/E ratio of -9.41.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Read More on FULC: